AR113454A1 - IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1 - Google Patents

IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1

Info

Publication number
AR113454A1
AR113454A1 ARP180103021A ARP180103021A AR113454A1 AR 113454 A1 AR113454 A1 AR 113454A1 AR P180103021 A ARP180103021 A AR P180103021A AR P180103021 A ARP180103021 A AR P180103021A AR 113454 A1 AR113454 A1 AR 113454A1
Authority
AR
Argentina
Prior art keywords
agents
inhibit
asgr1
compositions
asialoglycoprotein
Prior art date
Application number
ARP180103021A
Other languages
Spanish (es)
Inventor
Bruce D Given
Rui Zhu
Zhen Li
Tao Pei
Stacey Melquist
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of AR113454A1 publication Critical patent/AR113454A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente memoria da a conocer composiciones y métodos para la inhibición de la expresión génica del receptor de asialoglicoproteína 1 (ASGR1). Se dan a conocer agentes de interferencia de ARN (iARN), por ejemplo, agentes iARN de doble hebra, y conjugados agente iARN-ligando dirigido a la diana para inhibir la expresión de un gen ASGR1. También se dan a conocer composiciones farmacéuticas que comprenden uno o más agentes iARN ASGR1, opcionalmente con uno o más agentes terapéuticos adicionales. Los agentes iARN ASGR pueden utilizarse en métodos para el tratamiento de varias enfermedades y condiciones, tales como enfermedades cardiometabólicas asociadas con niveles elevados de colesterol distinto de HDL (no-HDL-C), niveles elevados de colesterol LDL (LDL-C), niveles elevados de colesterol total, y/o niveles elevados de triglicéridos (TG).The present specification discloses compositions and methods for the inhibition of asialoglycoprotein receptor 1 (ASGR1) gene expression. RNA interference agents (iRNAs) are disclosed, eg, double-stranded iRNAs, and iRNA-targeting ligand conjugates to inhibit the expression of an ASGR1 gene. Also disclosed are pharmaceutical compositions comprising one or more ASGR1 iRNA agents, optionally with one or more additional therapeutic agents. ASGR iRNA agents can be used in methods for the treatment of various diseases and conditions, such as cardiometabolic diseases associated with elevated levels of non-HDL cholesterol (non-HDL-C), elevated levels of LDL cholesterol (LDL-C), levels elevated total cholesterol, and / or elevated levels of triglycerides (TG).

ARP180103021A 2017-10-17 2018-10-17 IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1 AR113454A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762573206P 2017-10-17 2017-10-17

Publications (1)

Publication Number Publication Date
AR113454A1 true AR113454A1 (en) 2020-05-06

Family

ID=70857314

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103021A AR113454A1 (en) 2017-10-17 2018-10-17 IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1

Country Status (1)

Country Link
AR (1) AR113454A1 (en)

Similar Documents

Publication Publication Date Title
ZA202106265B (en) Compositions and methods for inhibiting gene expression of lpa
CL2020000593A1 (en) Rnai agents and compositions to inhibit the expression of apoliprotein c-iii (apoc3).
ECSP20018305A (en) IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE
CL2021001195A1 (en) Iarn agents for infection caused by the hepatitis b virus. (divisional application 201900278)
BR112016029041A8 (en) use of a glutaminase inhibitor, pharmaceutical composition and pharmaceutical kit
BR112017018318A2 (en) A pharmaceutical composition for treating cancer comprising a micro RNA as an active ingredient
BR112017009647A2 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors to treat alzheimer's disease
MX346439B (en) Methods and means to modify a plant genome.
BR112016029781A2 (en) compositions and methods for inhibiting alpha-1 antitrypsin gene expression
BR112014032239A2 (en) inhibitors of the micro-rnas mir-15 family
EA201792103A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES
MX2017005861A (en) Methods to target transcriptional control at super-enhancer regions.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
UY37936A (en) IRAN AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF THE ASIALOGLICOPROTEIN RECEIVER 1
BR112018010736A2 (en) antisense oligonucleotides against il-34 and methods of using them
AR113454A1 (en) IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1
BR112014013374A8 (en) Acamprosate Pills and Uses of Acamprosate
AR106227A1 (en) COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA)
AR113254A1 (en) IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE
AR109293A1 (en) IRN AGENTS FOR INFECTION WITH THE HEPATITIS B VIRUS
AR113014A1 (en) IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)
BR112014033118A8 (en) PHARMACEUTICAL COMBINATIONS OF A CDK4/6 INHIBITOR AND A B-RAF INHIBITOR

Legal Events

Date Code Title Description
FB Suspension of granting procedure